GlassScriptPhysician profile
Steven M Cardenas
NPI 1376212050
$6,687.31
in general payments reported to CMS, 2019-2025
29 companies · $2,111 in 2025
The $2,111 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $31.53 · 2023: $1,221 · 2024: $2,841 · 2025: $2,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,173.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,638.02 | 2021-2025 | Descovy, Biktarvy, Yeztugo |
| Viiv Healthcare Company | $1,838.24 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Novo Nordisk INC | $468.97 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $175.93 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $170.39 | 2024-2025 | Trogarzo, Egrifta |
| Emd Serono, INC. | $157.69 | 2023-2025 | Serostim |
| Lilly USA, LLC | $144.63 | 2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $136.75 | 2023-2025 | |
| Amgen INC. | $120.71 | 2024-2025 | Otezla, Repatha, Otezla |
| Janssen Products, LP | $99.00 | 2021 | |
| Hologic Sales and Service, LLC | $78.25 | 2024-2025 | Aptima |
| Janssen Biotech, INC. | $75.54 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $61.81 | 2024-2025 | Tlando |
| Napo Pharmaceuticals INC | $56.22 | 2023-2025 | Mytesi |
| Exact Sciences Corporation | $55.96 | 2023-2024 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.94 | 2021-2025 | Spravato |
| Sumitomo Pharma America, INC. | $47.80 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $45.23 | 2024-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.70 | 2023 | Jardiance, Synjardy |
| Lundbeck LLC | $35.40 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $34.61 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.11 | 2025 | Caplyta |
| Almatica Pharma LLC | $24.32 | 2025 | Loreev Xr |
| Pfizer INC. | $21.50 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.09 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $20.55 | 2023 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $16.61 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.52 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $13.82 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Cardenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.